Linking environmental agents and autoimmune disease: an agenda for future research. by Selgrade, M K et al.
Linking Environmental Agents and Autoimmune Disease: An Agenda for
Future Research
MaryJane K. Selgrade,1 Glinda S. Cooper,2 Dori R. Germolec,3 and Jerrold J. HeindeI4
1National Health and Environmental Effects Research Laboratory, U.S. Environmental Protection Agency, Research Triangle Park, North
Carolina USA; 2Epidemiology Branch, 3Laboratory ofToxicology, 4Division of Extramural Research and Training, National Institute of
Environmental Health Sciences, Research Triangle Park, North Carolina USA
Autoimmune diseases are influenced by multiple factors including genetics, age, gender,
reproductive status, hormones, and potential environmental contaminants. A workshop, "Linking
Environmental Agents and Autoimmune Diseases," was convened at the National Institute of
Environmental Health Sciences, Research Triangle Park, North Carolina, 1-3 September 1998, to
review current knowledge about links between environmental exposures and autoimmune disease,
to identify and prioritize research needs, and to develop an integrated, multidisciplinary research
agenda. Participatants spent the last half-day of the workshop in small group discussions for the
purpose of developing consensus on research needs. Research needs identified were a) develop
research tools needed to explore links between environmental agents and autoimmune disease;
b) establish a disease registry or surveillance system; c) develop and validate strategies for
screening chemicals for the potential to induce or exacerbate autoimmune disease; d) develop an
emergency response strategy to gain information from accidental exposures; and e) conduct
hypothesis-driven research in occupationally exposed groups and/or in experimental animals. There
was consensus that meetings like this workshop and projects that facilitate interactions between
specialties should be encouraged. A multidisciplinary approach is needed to address this problem.
Key words: autoimmune disease, epidemiology, hazard identification, research needs. - Environ
Health Perspect 107(suppl 5):81 1-813 (1999).
http.//ehpnetl.niehs.nih.gov/docs/1999/suppl-5/81 1-13selgrade/abstract.html
There are over 80 autoimmune diseases
affecting 10 million Americans. These dis-
eases are influenced by multiple factors
including genetics, age, gender, reproductive
status, hormones, and potential environmen-
tal contaminants. This monograph reports
the proceedings of the workshop "Linking
Environmental Agents and Autoimmune
Diseases" held at the National Institute of
Environmental Health Sciences, Research
Triangle Park, North Carolina, 1-3
September 1998. The workshop brought
together immunologists, clinicians, epidemi-
ologists, molecular biologists, and toxicol-
ogists to review current knowledge about
environmental links to autoimmune disease
and identify data gaps and future research
needs in a multidisciplinary fashion. The
articles in this monograph discuss this review
(conducted during the first 2 days of the
workshop). The final half-day ofthe work-
shop was devoted to developing a research
agenda, which is the topic of this article.
Speakers and participants met in small
groups to brainstorm on the following top-
ics: strategies for testing, common threads
(among autoimmune diseases, chemicals, and
other indicators of immunotoxicity), inte-
grating epidemiology and animal research,
organ-specific diseases, and risk factors (sen-
sitive populations). A summary of each
group's discussion was presented during the
last session ofthe workshop, and a consensus
on research needs and priorities (i.e., a
research agenda) was developed (Table 1).
Five broad research needs were identified and
are described below. The foremost need
(encompassed in the first four needs listed
below) is to develop a preliminary database
indicating a role for various environmental
agents in the development or progression of
various autoimmune diseases. The field can-
not move rapidly into hypothesis-driven
research (the fifth need listed below), particu-
larly with respect to molecular mechanisms,
without preliminary data on which agents
and diseases are important.
ResearchNeeds
Develop research tools needed to explore
links between environmental agents and
autoimmune disease. Because this field of
study is fairly new, many ofthe tools needed
to effectively study the links between environ-
mental agents and autoimmune disease must
be developed. Two much-needed tools are
biomarkers ofeffect and validated question-
naires for use in epidemiology, field, and clin-
ical studies. Superimposed on both ofthese is
a need to understand the role that other fac-
tors such as genetic polymorphisms, gender,
and infectious disease play in susceptibility to
and expression ofautoimmune disease.
Developing useful biomarkers inevitably
requires an understanding of the mecha-
nisms underlying autoimmune disease and
potential interactions among environmental
chemicals, the immune system, and target
organs. Two possible types ofchemical effects
are ofconcern: initiation ofautoimmune dis-
ease and exacerbation or acceleration of pre-
existing autoimmune disease. Biomarkers
amenable to both human and animal studies
would be ideal. A number ofpotential candi-
dates were discussed, including the presence
of autoantibodies or autoreactive T cells;
alterations in T cells, B cells, and macro-
phages; increased total immunoglobulin G;
human leukocyte antigen/major histocompat-
ibility complex markers; and expression of
cell surface proteins assessed by flow cytome-
try, serum enzymes, and cytokine profiles.
There may be others as well. It was suggested
that clinical trials (e.g., stage III drug trials)
or groups exposed occupationally (e.g., to sil-
ica, pesticides, or anesthesia), as well as ani-
mal models of certain diseases may provide
opportunities to address this issue. The most
expedient solution would be the identifica-
tion ofbiomarkers universal to all types of
autoimmune disease; however, there are
likely multiple mechanisms involved in the
development of different autoimmune dis-
eases. These different mechanisms will prob-
ably result in the need to develop different
assays and biomarkers for certain auto-
immune diseases. The complexity ofautoim-
mune disease(s) is not unlike that associated
with cancer. Certainly, the identification of
mechanisms common to more than one type
ofautoimmune disease would yield the most
useful biomarkers. For example, with the
advent of cDNA microarray technology, it
may be possible to identify patterns ofgene
expression that meet this criterion.
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Table 1. Research needs.a
Develop research tools needed to explore environmental agents/autoimmune disease links
Establish a disease registry or surveillance system.
Develop and validate strategies for screening chemicals
Develop an emergency response strategy to gain information from accidental exposures
Conduct hypothesis-driven research in exposed groups and/or in experimental animals
"The foremost need (encompassed in the first four needs listed above) is to develop a preliminary database. The field cannot move
rapidly into hypothesis-driven research without preliminary data on which agents and diseases are important.
Validated questionnaires are needed for
use in cohort and other types ofepidemiology
studies to assess exposure and both organ-
specific and systemic effects that might be
associated with chronic, low-dose (or occa-
sionally acute, high-dose) exposures. Again,
questionnaires need to consider two possibili-
ties: initiation, or possible exacerbation/accel-
eration of autoimmune disease. In the first
case the population at large may be at risk. In
the second case a genetically sensitive sub-
population is at risk. Another concern is that
autoimmune disease associated with chemical
or drug exposure may differ somewhat from
spontaneously occurring autoimmune disease;
a related concern is that diagnostic criteria
used for clinical research (prognosis and ther-
apy) may not be appropriate or optimal for
etiologic research.
Establish a nationwide surveillance
network. Population-based registries for
autoimmune diseases would help to identify
clusters of cases potentially associated with
environmental exposures as well as sensitive
populations. Because individually most
autoimmune diseases are relatively rare, sur-
veillance ofthis type is needed to define the
scope and magnitude ofthe problem. Essential
to establishing such a surveillance network is a
working definition (diagnostic criteria) of
autoimmune disease. In developing a defini-
tion, the possibility should be considered that
autoimmune diseases associated with chemical
exposures may not be identical to spontaneous
disease as mentioned above. There are a num-
ber ofapproaches that may be used to develop
registries, including state-based or disease-
specific registries. A variety ofdesigns should
be explored, as it is unclear which approaches
will be most useful. Ultimately, strategies must
be designed that include rural and minority
populations. Registries are necessary to stimu-
late and facilitate research and reduce the like-
lihood that biases in selection ofpatients will
produce inaccurate study results. A related
activity, the development ofcell (DNA) and
sera banks on selected populations, would also
facilitate research with respect to genetic
predisposition, for instance.
Develop and validate strategiesfor
screening chemicalsfor thepotential to
induce or exacerbate autoimmune disease.
The goal is to develop a testing strategy, most
likely in laboratory rodents, that could be
used to assess chemicals for the potential to
increase risks associated with autoimmune
disease. The National Toxicology Program
(NTP) (1) testing battery that is used to
assess immune suppression is an example of
such a strategy.
The first step is to develop tools for hazard
identification. Few tests amenable to screening
are currently available. During the workshop
there was considerable discussion of the
popliteal lymph node assay (PLNA) and the
modified PLNA using reporter antigens (2).
There was general agreement that an interna-
tional, interlaboratory evaluation of these
assays would be valuable and should include a
broad range ofchemical classes. Ideally, both
known positives and negatives should be
included in the validation of this assay,
although identifying chemicals with these
characteristics may be difficult. The possibility
that a metabolite rather than the parent com-
pound might be responsible for an effect has
to be taken into account. Such a validation
effort should provide information on repro-
ducibility ofthe assay as well as an indication
ofthe potential for false negatives and false
positives. It is unknown at this point whether
this assay can distinguish between initiators
and potentiators. The workshop participants
recognized that the PLNA, in its current
form, identifies immunostimulatory com-
pounds, not specific agents responsible for
autoimmune effects. Further development of
this assay to more specifically target autoim-
mune disease should be encouraged. There
was also some interest in exploring the poten-
tial of other types of assays that detect
immune stimulation as possible screening tests
to begin to identify agents posing a risk of
autoimmune disease. In particular, the
recently revised Organization for Economic
Co-operation and Development 407 guide-
lines (3) or the NTP-tiered testing approach
(1) has produced considerable data on
immune modulation. Because these tests were
designed to assess immune suppression, the
data have not been analyzed to determine
their value in identifying agents that might
cause or contribute to autoimmune disease.
However, it may be that for some of these
chemicals, stimulation ofa response occurred
and was probably ignored. Because data from
these tests are already available for a number
ofchemicals and certain ofthese tests are now
being required in some cases (4), an analysis
oftheir value in identifying chemicals associ-
ated with autoimmune disease should be
fairly straightforward and would yield valu-
able information. One concern is that these
assays may need to be repeated in animals
that are genetically predisposed to developing
autoimmune disease (e.g., NZB/W mice) in
order to address the possibility of exacerba-
tion of disease versus initiation. Beyond
screening for immunostimulatory effects, a
number ofthepotential biomarkers listed ear-
lier under developing research tools, as well as
histopathology on selected organs, may also
prove useful for screening purposes. In addi-
tion, there was a suggestion that it is possible
to develop in vitro assays that provide a
preliminary screening test.
Finally, it is necessary to continue to
evaluate the use ofcurrently available animal
models of autoimmune disease and to
develop additional animal models that may
be used to identify environmental agents that
potentiate systemic andorgan-specific disease.
Again, this requires a clear definition of
autoimmune disease against which to assess
the appropriateness of the animal models.
Guidelines to be used in selecting appropriate
animal models for testing suspect chemicals
also must be developed. These guidelines
should consider chemical structures, any
observed clinical manifestations, types of
immunostimulatory responses observed in
screening studies, genetic predisposition, gen-
der, and other issues. Animal models ulti-
mately could be used to identify genetic
targets and polymorphisms in these genes
that could altersusceptibility. The presence of
similar polymorphisms in homologous
human genes would certainly support the
appropriateness ofan animal model.
Once testing strategies have been
developed, an assessment is needed to deter-
mine whether rodents are good predictors of
the potential to induce or potentiate autoim-
mune disease compared to clinical and epi-
demiologic data. Other issues more easily
addressed after the above issues have been
resolved include consideration of the most
appropriate tests/methods to assess auto-
immune effects that might result from prena-
tal exposures or from longer term chronic
exposures, particularly in the elderly. Also,
once a database is established, it is important
to consider structure-activity relationships
associatedwith autoimmune disease.
Develop an emergency response strategy.
On occasion there have been large-scale acci-
dental exposures (toxic oil) or unexpected
effects from intended exposures (L-trypto-
phan) that may have yielded more informa-
tion had someone been prepared to assess the
situation in a timely fashion. A protocol for
responding to such incidents must be in place
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in advance, along with the means to rapidly
obtain support, both financial and other (e.g.,
rapid institutional review board approval).
Both clinical and epidemiologic approaches
as well as exposure assessment must be
included in such a strategy. This issue is not
unique to autoimmune disease effects, and
any emergency response strategy could be
extended to include immune modulatory
effects in general. Because ofthe resilience of
the immune response, it is important to assess
effects as soon as possible after exposure and
to conduct exposure assessment. A result of
such emergency response studies is the gener-
ation ofhypotheses that could then be tested
in controlled animal studies or perhaps in the
exposed population.
Conduct hypothesis-driven research in
occupationally exposedgroups and/or in
experimentalanimals. Hypotheses generated
from case reports, clusters identified in sur-
veillance studies, and the previously men-
tioned emergency response efforts must be
tested in a strictly controlled fashion a.
Identification ofautoimmune effects after
chemical exposure in animal studies should
result in the development ofhypothesis-
driven human epidemiologic or clinical
studies. Wherever possible, attempts must be
made to link human and animal research. For
example, considerable data describing the
development of thyroiditis in animals
exposed to dietary iodine were presented at
this meeting (5), but no epidemiologic
studies to assess the association between
dietary iodine and thyroiditis in humans have
been conducted. Similarly, animal data sug-
gest an association between certain chemical
exposures (e.g., mercury, trichloroethylene)
and autoimmune disease, but there are no
human data to substantiate these results
(6-8). On the other hand, the association
between certain chemical exposures (e.g.,
vinyl chloride; silica) and scleroderma has
been studied in clinical settings (Parks et al.,
this monograph (9), but currently there are
no data from animal models that test the
hypothesis that exposure to these chemicals
contributes to this disease. It is clear that
some coordination ofhuman and animal
studies is needed to maximize our ability to
use the data to assess the risk of auto-
immune disease that might be associated
with chemical exposure.
A number of major research questions
were raised during the discussions that should
be addressed in a hypothesis-driven manner:
Are there gender differences in susceptibility
to specific environmental agents? What
genetic polymorphisms are critical in the
development ofautoimmune disease follow-
ing chemical exposure? What is the role of
the endocrine system? Are there distinct path-
ways leading to distinct systemic autoimmune
diseases or do systemic autoimmune diseases
share common etiologic risk factors? Are
there clinical and/or mechanistic differences
between idiopathic and chemically induced
autoimmune diseases? Can exposure to an
environmental agent exacerbate the natural
history ofan autoimmune disease? Do envi-
ronmental factors (other than infectious
agents) play any role in the development of
type I diabetes? Does in utero exposure pose a
risk ofsubsequent development of auto-
immune disease? Ifso, what are the most sen-
sitive periods for exposure? Does exposure
during other developmental stages (neonatal,
prepubertal, adult, aged) influence the risk of
developing autoimmune disease? Is there syn-
ergybetweenviral infection andenvironmental
chemicals in the development ofautoimmune
disease? There are certainly other questions
thatcould be raised aswell.
AFnalRecommendation
There was consensus that meetings like this
one and projects that facilitate interactions
between specialties should be encouraged.
Funding should be targeted to integrated
studies that use multidisciplinary approaches
to improve overall knowledge ofthe hazard,
mechanism of action, and human health
consequences associated with environmental
agents and autoimmune disease. Meetings of
this typeshouldbeheldperiodicallyas ameans
of exchanging information and focusing
research to gain maximum benefit.
Addendum
The congressional budget for the National
Institutes ofHealth (NIH) for 1999, which
came out shordy after this conference, appro-
priated $30 million for research on auto-
immune diseases. One project that will use
this money is a Request for Applications
(RFA), jointly sponsored by the National
Institute ofEnvironmental Health Sciences
and several other NIH institutes, that is a
direct result ofthe research ideas put forth at
this conference and detailed above. The RFA
"Environment-Infection-Gene Interactions in
Autoimmune Diseases" will fund pilot/feasi-
bility studies to determine the role ofenviron-
mental agents (chemical, physical, infectious)
and genetics in the initiation and progression
ofautoimmune diseases.
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